Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera

September 21st 2023

The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21st 2023

Uwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s investigation in patients with lower-risk MDS who are transfusion independent.

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

September 20th 2023

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

September 19th 2023

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

Dr Kuykendall on the FDA Approval of Momelotinib in Myelofibrosis

September 15th 2023

Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.

FDA Approves Momelotinib for Myelofibrosis With Anemia

September 15th 2023

The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.

Ruxolitinib in the Treatment of PV

September 15th 2023

Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

September 15th 2023

Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.

NICE Recommends Ruxolitinib for Hydroxycaramide/Hydroxyurea Resistant or Intolerant Polycythemia Vera

September 14th 2023

The National Institute for Health and Care Excellence has published its Final Draft Guidance recommending the use of ruxolitinib as treatment for eligible patients in England and Wales with polycythemia vera that is resistant or intolerant to hydroxycarbamide/hydroxyurea.

JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis

September 12th 2023

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.

Dr Hunter on the Current Treatment Landscape of JAK Inhibitor Treatment in Myelofibrosis

September 11th 2023

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

September 9th 2023

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Survival Outcomes May Be Impacted By Socio-Racial Factors in Primary Myelofibrosis

September 8th 2023

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

Treatment Approaches for High-Risk Patients With PV

September 8th 2023

Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.

Key Trials in the Treatment of PV

September 8th 2023

Experts review critical trial data in the treatment of patients with polycythemia vera.

Health Outcomes in Hematologic Malignancies Impacted By Insurance, Marital, and Economic Status

September 7th 2023

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS

September 7th 2023

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

Prognostic Model Could Help Predict Survival Outcomes for Patients With Myelofibrosis Undergoing AlloHCT

September 6th 2023

A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Renin Angiotensin Inhibitors Reduce Thrombotic Adverse Effects in Chronic Myeloproliferative Neoplasms

September 5th 2023

Patients with essential thrombocythemia and polycythemia vera who also had arterial hypertension experienced a higher cumulative incidence of thrombotic adverse effects compared with those without hypertension and fewer thrombotic complications following treatment with renin angiotensin system inhibitors.

Momelotinib Could Represent Pivotal New Treatment Option in Myelofibrosis

September 1st 2023

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.